Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...
Arvinas price target lowered to $12 from $48 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...
PharmExec5h
Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Fintel on MSN15h
Wedbush Downgrades Arvinas (ARVN)
Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...
Zacks Investment Research on MSN2h
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Arvinas price target lowered to $32 from $57 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after ...
BioSpace1h
Amgen’s Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...